New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient’s risk of developing certain cancers. This is mainly for the better. A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists – such as Ozempic, Wegovy, Mounjaro, and Zepbound –…